Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Nektar Therapeutics (NKTR) Starts Presentation at 25th Annual ROTH Conference

Posted on March 19, 2013 by Mission IR

Nektar Therapeutics is a biopharmaceutical company engaged in the development of novel therapeutics based on the company’s PEGylation and advanced polymer conjugation technology platforms. The company’s R&D pipeline consists of potentially high-value therapeutics in pain, oncology and other therapeutic areas. NKTR’s proprietary candidate, NKTR-181, is a novel mu-opioid analgesic in phase 2 development in osteoarthritis patients with chronic knee pain. For more information, visit the company’s Web site: http://www.nektar.com

Let us hear your thoughts below:

This year's annual ROTH Conference will take place at The Ritz Carlton located in Laguna Niguel, on March 17-12, 2013. Bringing together executives from more than 400 growth companies, the ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com.
This entry was posted in ROTH Capital Partners Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *